RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small.
The Pharma Data
AUGUST 19, 2021
1 Disease response was evaluated using overall response rate (ORR), per Response Evaluation Criteria in Solid Tumors Version 1.1* (RECIST v1.1) Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. “We In 2018, Janssen Biotech, Inc. Interstitial Lung Disease/Pneumonitis 7.
Let's personalize your content